Precision Oncology Market By Product Type (Companion Diagnostics, Genomic Testing Kits, Liquid Biopsy), By Application (Cancer Diagnosis, Personalized Cancer Treatment, Tumor Profiling), By End-User (Hospitals, Diagnostic Laboratories, Research Institutions, Pharmaceutical Companies), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Precision Oncology Market was valued at USD 78.4 billion in 2024-e and will surpass USD 123.6 billion by 2030; growing at a CAGR of 7.9% during 2025 - 2030.

The precision oncology market is experiencing rapid growth, driven by advancements in genomics, biotechnology, and personalized medicine. Precision oncology aims to tailor cancer treatment based on the genetic and molecular characteristics of both the patient and their tumor, ensuring the most effective therapies are chosen for individual cases. By utilizing targeted therapies, immunotherapies, and other personalized approaches, precision oncology seeks to enhance treatment outcomes, reduce side effects, and improve overall survival rates for cancer patients. The increasing availability of genomic data and advancements in diagnostic technologies are key factors driving the expansion of this market.

The growing understanding of cancer at the molecular level, combined with innovations in companion diagnostics and tumor profiling, is reshaping how oncology treatments are developed and administered. This shift from one-size-fits-all to individualized treatment plans is significantly improving the efficiency of cancer care. As the demand for more effective, targeted therapies rises, precision oncology continues to gain traction across various cancer types, with significant investments being made in research and technology to further advance personalized cancer treatment strategies.

Companion Diagnostics Product Type is Largest Owing to Improved Treatment Accuracy

Companion diagnostics is the largest product type in the precision oncology market, owing to its critical role in ensuring the accuracy and effectiveness of personalized cancer treatments. Companion diagnostics tests are designed to identify specific genetic mutations or biomarkers in a patient’s tumor, which helps determine the most suitable therapeutic options. These tests are especially important for guiding the use of targeted therapies, such as biologics and immunotherapies, ensuring that patients receive treatments most likely to provide a positive outcome.

The growing emphasis on personalized cancer care has significantly increased the demand for companion diagnostics, particularly in oncology, where treatments are becoming more tailored to individual patient profiles. With the approval of more targeted therapies, companion diagnostics are essential for selecting the right patients who are likely to benefit from these advanced treatments. This makes companion diagnostics the largest segment in the precision oncology market, as it plays a pivotal role in improving the efficacy of cancer therapies and reducing unnecessary treatments.

Genomic Testing Kits Technology is Fastest Growing Owing to Advancements in Early Detection

Genomic testing kits are the fastest-growing technology in the precision oncology market, driven by their ability to provide comprehensive genetic profiling of tumors and patients. These kits enable early detection of genetic mutations that may drive cancer development, offering a powerful tool for diagnosing cancer and identifying potential risks in asymptomatic individuals. The ability to detect genetic alterations at an early stage is crucial for enabling timely intervention and personalized treatment, ultimately improving cancer outcomes.

The increasing use of genomic testing kits in clinical settings is further fueled by the rapid advances in sequencing technologies, such as next-generation sequencing (NGS), which allow for faster, more accurate, and cost-effective genetic analysis. As genomic testing becomes more accessible, it is expected to play an even more significant role in early cancer diagnosis and prevention, particularly in high-risk populations. The growing trend of preventive healthcare and personalized medicine will continue to drive the adoption of genomic testing kits, making them the fastest-growing technology in precision oncology.

Personalized Cancer Treatment Application is Largest Owing to Targeted Therapy Demand

Personalized cancer treatment is the largest application segment in the precision oncology market, owing to the increasing demand for targeted therapies that are specifically designed to address the genetic and molecular makeup of individual tumors. Unlike traditional treatments, which often rely on a one-size-fits-all approach, personalized cancer treatments aim to maximize efficacy while minimizing adverse effects by selecting therapies based on a patient’s unique genetic profile. This shift is significantly improving treatment outcomes and patient quality of life, particularly in complex cancers such as breast cancer, lung cancer, and melanoma.

The growing body of research supporting personalized oncology, combined with the rising approval of targeted therapies and immunotherapies, is further driving the demand for personalized cancer treatments. Companion diagnostics and genomic testing play a vital role in guiding the selection of these therapies, ensuring that patients receive the most appropriate treatment for their specific cancer type. As more therapies are developed to target specific mutations, the personalized cancer treatment application will continue to be the largest and most significant segment in the precision oncology market.

North America Region is Largest Owing to Strong Research and Healthcare Systems

North America is the largest region in the precision oncology market, owing to its advanced healthcare infrastructure, well-established research institutions, and high adoption of cutting-edge oncology treatments. The United States, in particular, is a leader in precision oncology, with a robust regulatory framework supporting the approval of targeted therapies and companion diagnostics. The FDA’s approval of numerous precision oncology treatments and diagnostic tools has significantly boosted the market, ensuring that patients have access to the latest advancements in cancer care.

In addition to strong healthcare systems, North America is home to leading biotechnology and pharmaceutical companies, as well as academic and research institutions, which are driving innovation in the field of precision oncology. The region’s focus on personalized healthcare, along with a growing number of clinical trials and research initiatives, positions North America as the dominant region in the global precision oncology market. As the demand for personalized treatments continues to rise, North America is expected to maintain its leadership in the market.

Leading Companies and Competitive Landscape

Leading companies in the precision oncology market include Roche, Thermo Fisher Scientific, Illumina, Agilent Technologies, and Abbott Laboratories. These companies are at the forefront of developing and delivering cutting-edge diagnostic tools, genomic testing kits, and companion diagnostics that are essential for personalized cancer treatments. Their focus on advancing technologies such as next-generation sequencing, liquid biopsy, and immunotherapies has positioned them as key players in the market.

The competitive landscape in the precision oncology market is highly dynamic, with both large multinational corporations and specialized startups vying for market share. Companies are increasingly focusing on strategic collaborations, acquisitions, and partnerships to expand their portfolios and enhance their capabilities in precision oncology. With ongoing innovations in genomics, personalized medicine, and biotechnology, the market is expected to remain competitive, with companies striving to lead in the development of targeted therapies and diagnostic solutions that can improve cancer treatment outcomes globally.

List of Leading Companies:

• Roche Diagnostics
• Thermo Fisher Scientific
• Illumina, Inc.
• Qiagen N.V.
• Agilent Technologies
• Bio-Rad Laboratories
• Abbott Laboratories
• GE Healthcare
• Hologic, Inc.
• PerkinElmer, Inc.
• Becton Dickinson and Company
• LabCorp
• Merck & Co., Inc.
• Novartis AG
• Foundation Medicine

Recent Developments:

• In December 2024, Roche Diagnostics launched a new genomic testing solution aimed at enhancing precision oncology treatment plans.
• In November 2024, Illumina, Inc. introduced a next-generation sequencing platform to improve the accuracy of cancer genomics.
• In October 2024, Thermo Fisher Scientific partnered with a leading pharmaceutical company to develop personalized cancer therapies based on genomic data.
• In September 2024, Qiagen N.V. released a new companion diagnostic kit for personalized cancer treatment in oncology.
• In August 2024, Foundation Medicine expanded its tumor profiling capabilities to include additional cancer types for better-targeted therapy decisions.

Report Scope: